PMC:7195088 / 22306-22685 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"644","span":{"begin":247,"end":253},"obj":"Gene"},{"id":"678","span":{"begin":13,"end":21},"obj":"Species"},{"id":"810","span":{"begin":163,"end":172},"obj":"Chemical"},{"id":"811","span":{"begin":173,"end":193},"obj":"Chemical"},{"id":"812","span":{"begin":276,"end":285},"obj":"Chemical"},{"id":"945","span":{"begin":27,"end":35},"obj":"Disease"}],"attributes":[{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Gene:1576"},{"id":"A678","pred":"tao:has_database_id","subj":"678","obj":"Tax:9606"},{"id":"A810","pred":"tao:has_database_id","subj":"810","obj":"MESH:D000069454"},{"id":"A812","pred":"tao:has_database_id","subj":"812","obj":"MESH:D000069454"},{"id":"A945","pred":"tao:has_database_id","subj":"945","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T16","span":{"begin":200,"end":203},"obj":"Body_part"}],"attributes":[{"id":"A16","pred":"fma_id","subj":"T16","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T14","span":{"begin":146,"end":151},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T108","span":{"begin":27,"end":35},"obj":"Disease"}],"attributes":[{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T108","span":{"begin":128,"end":131},"obj":"http://purl.obolibrary.org/obo/CLO_0001608"},{"id":"T109","span":{"begin":245,"end":246},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T258","span":{"begin":163,"end":172},"obj":"Chemical"},{"id":"T259","span":{"begin":173,"end":183},"obj":"Chemical"},{"id":"T260","span":{"begin":184,"end":193},"obj":"Chemical"},{"id":"T261","span":{"begin":211,"end":229},"obj":"Chemical"},{"id":"T263","span":{"begin":220,"end":229},"obj":"Chemical"},{"id":"T264","span":{"begin":247,"end":263},"obj":"Chemical"},{"id":"T265","span":{"begin":254,"end":263},"obj":"Chemical"},{"id":"T266","span":{"begin":276,"end":285},"obj":"Chemical"},{"id":"T267","span":{"begin":333,"end":342},"obj":"Chemical"},{"id":"T268","span":{"begin":343,"end":353},"obj":"Chemical"}],"attributes":[{"id":"A258","pred":"chebi_id","subj":"T258","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A259","pred":"chebi_id","subj":"T259","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"},{"id":"A260","pred":"chebi_id","subj":"T260","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A261","pred":"chebi_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A262","pred":"chebi_id","subj":"T261","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A263","pred":"chebi_id","subj":"T263","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A264","pred":"chebi_id","subj":"T264","obj":"http://purl.obolibrary.org/obo/CHEBI_86501"},{"id":"A265","pred":"chebi_id","subj":"T265","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A266","pred":"chebi_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A267","pred":"chebi_id","subj":"T267","obj":"http://purl.obolibrary.org/obo/CHEBI_367163"},{"id":"A268","pred":"chebi_id","subj":"T268","obj":"http://purl.obolibrary.org/obo/CHEBI_72291"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}

{"project":"LitCovid-sentences","denotations":[{"id":"T164","span":{"begin":37,"end":90},"obj":"Sentence"},{"id":"T165","span":{"begin":91,"end":162},"obj":"Sentence"},{"id":"T166","span":{"begin":163,"end":230},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"d of care in patients with COVID-19. Double-blind, adaptive RCT (NCT04315948, recruiting). Primary endpoint: severity rating on a 7-point ordinal scale at day 15.\nDarunavir/cobicistat Darunavir is an HIV type 1 protease inhibitor. Cobicistat is a CYP3A4 inhibitor that boosts darunavir concentrations • Not available • Comparison of darunavir/cobicistat vs. standard of care in p"}